Evaluation of ReX-C System in Measurement and Improvement of Patients' Adherence.

Launched by DOSENTRX LTD. · Jan 31, 2018

Keywords

ClinConnect Summary

This clinical trial is studying a new system called ReX-C, which is designed to help patients take their medications correctly and improve how well they stick to their treatment plans. The focus is on patients who are receiving medications called anti-coagulants, which are used to prevent serious blood clots that can lead to conditions like strokes or deep vein thrombosis. The trial will evaluate how safe, easy to use, and effective the ReX-C system is for these patients.

To participate, individuals need to be at least 18 years old and currently taking specific anti-coagulant medications for at least a month. They should be able to swallow pills and use the ReX-C device without any major difficulties. Participants will have the chance to help researchers understand how well this new system works, and they will be involved in a process to ensure they're taking their medications as prescribed. This trial is currently looking for volunteers, and it could be an important step in improving medication management for patients with thromboembolism.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or Female, at least 18 years of age
• • 2. Subject is able to swallow pills and use ReX-C device to receive medication.
• • 3. Subject is able to read and understand the Informed Consent Form.
• • 4. Subject receives anti-coagulants for the treatment and prevention of thromboembolism events, (e.g: Arterial Fibrillation (AF), Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)).
• • 5. Subject receives Novel Oral Anti-coagulant (NOAC); including; Pradaxa® (dabigatran), Xarelto® (rivaroxaban) and Eliquis® (apixaban).
• • 1. Subject is recruited at least 1 month after treatment initiation and has stable dose regime.
• • 2. Subject receives stable dose of medication for at least a month.
• • 6. Subject takes medication therapy at home.
• Exclusion Criteria:
• • 1. Subject has significant physical disability including; poor fine motor skills, impaired visual or auditory faculties, mental disorders or other impairment affecting ability to provide Informed Consent Form or use the ReX-C dispensing unit effectively.
• • 2. Subject cen not use ReX-C to receive medications.
• • 3. Subject is participating in another clinical study that does not permit participation in two studies simultaneously.
• • 4. Subject is at end stage or terminal illness with anticipated life expectancy of 6 months or less.
• • -